Coya Therapeutics, Inc. issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase…
Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Compa
How this was made
The 30-second read
Why it matters
Full enrollment moves the program into the double‑blind treatment phase, setting the stage for data readout in early 2027.
Market read
Trial enrollment is a material milestone for a small‑cap biotech, potentially influencing its valuation ahead of data release.
What to watch
The trial still faces a long timeline; cash runway and upcoming data releases could dominate price action.
Background
Coya Therapeutics is a clinical‑stage biotech developing low‑dose IL‑2 and CTLA‑4 Ig combination for ALS.
Ticker impact
Coya Therapeutics announced full enrollment of 120 patients in its Phase 2/3 ALS trial, a first‑time disclosure of trial progress.
likely modest upside as investors price in potential positive Phase 2/3 data
First report of enrollment signals progress; biotech stocks often rally on trial milestones.
Market effects
May boost interest in ALS therapeutic pipeline and related biotech peers.
Limited to US biotech sector.
Minor, confined to specialty pharma investors.
Counterpoint
If the trial fails to meet endpoints, the enrollment news could be a false positive and lead to a sell‑off.
Key entities
- companyCoya Therapeutics, Inc.
Biotech firm conducting the ALSTARS ALS trial.
- executiveArun Swaminathan, Ph.D.
CEO of Coya Therapeutics, signatory of the 8‑K filing.
